Table 5: Details in patients with brain metastases.
| Number of patients (%) | ||
| Total | 14 | |
| Number of previous regimens for metastatic breast cancer | ||
| 0 | 0 | |
| 1 | 4 (29%) | |
| 2 | 2 (14%) | |
| 3 | 4 (29%) | |
| ≥ 4 | 4 (29%) | |
| Loco-regional treatment for brain metastases | ||
| None | 1 (7%) | |
| Surgery | 0 | |
| Radiation therapy | 12 (86%) | |
| Surgery + radiation therapy | 1 (7%) | |
| Response to T-DM1 for brain metastases | ||
| Complete response | 0 | |
| Partial response | 0 | |
| Stable disease | 5 (36%) | |
| Progressive disease | 5 (36%) | |
| Not evaluable | 4 (29%) | |
| Median time to treatment failure, months (range) | 6.0 (0.8-21.0) | |
| Adverse events (Grade 3/4) | ||
| Thrombocytopenia | 3 (21%) | |
| Increased ALT and/or AST | 0 | |
| Rash | 0 | |
| Neutropenia | 0 | |